DaVita (NYSE:DVA) Trading Down 5.3% – Should You Sell?

DaVita Inc. (NYSE:DVA) dropped 5.3% during mid-day trading on Thursday . The company traded as low as $184.18 and last traded at $183.4890. Approximately 621,564 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 917,575 shares. The stock had previously closed at $193.86.

Analyst Ratings Changes

DVA has been the subject of several recent analyst reports. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and upped their price target for the stock from $201.00 to $220.00 in a research note on Friday, August 7th. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial cut their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Barclays boosted their price target on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $233.43.

DaVita Price Performance

The firm has a fifty day moving average price of $201.51 and a two-hundred day moving average price of $186.53. The stock has a market capitalization of $11.71 billion, a PE ratio of 14.99, a P/E/G ratio of 0.49 and a beta of 0.83.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same period in the previous year, the company earned $2.95 EPS. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts expect that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC lifted its holdings in DaVita by 6.2% during the second quarter. Sequoia Financial Advisors LLC now owns 2,791 shares of the company’s stock worth $621,000 after buying an additional 164 shares during the period. IPG Investment Advisors LLC purchased a new stake in shares of DaVita during the 2nd quarter worth $1,938,000. Integrated Wealth Concepts LLC boosted its holdings in shares of DaVita by 164.5% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 10,530 shares of the company’s stock valued at $2,343,000 after buying an additional 6,549 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of DaVita by 66.4% in the 2nd quarter. NewEdge Advisors LLC now owns 361 shares of the company’s stock worth $80,000 after buying an additional 144 shares during the last quarter. Finally, IFP Advisors Inc grew its position in shares of DaVita by 32.4% in the 2nd quarter. IFP Advisors Inc now owns 437 shares of the company’s stock worth $97,000 after buying an additional 107 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.